Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer

We report the impact of SAbR on tumor control rates as well as its tolerability in systemic therapy –naïve patients with oligometastatic disease (without brain metastases) and assess the effect of SAbR on subsequent first line systemic therapy by comparison to historical controls.

Source: International Journal of Radiation Oncology * Biology * Physics - July 30, 2019 Category: Radiology Authors: Yuanyuan Zhang, Jonathan Schoenhals, Alana Christie, Osama Mohamad, Chiachien Wang, Isaac Bowman, Nirmish Singla, Hans Hammers, Kevin Courtney, Aditya Bagrodia, Vitaly Margulis, Neil Desai, Aurelie Garant, Hak Choy, Robert Timmerman, James Brugarolas, Raq Tags: Clinical Investigation Source Type: research